Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FXB0871 in Advanced Solid Tumors, NSCLC, and HCC
NCT07558200Phase 1Not yet recruiting
- Sponsor
- Fosun Pharma
- Start
- May 2026
- Primary completion
- Apr 2030
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of FXB0871 in solid tumor, non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) (4 arms), sponsored by Fosun Pharma. Primary endpoints: Dose-Limiting Toxicities at 28 days, Adverse Events and 1 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
FXB0871
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07558200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07558200.